Cytosorbents Corp (CTSO) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $8. Maxim Group advised their investors in a research report released on May 24, 2016.
Cytosorbents Corp opened for trading at $4.25 and hit $4.4 on the upside on Friday, eventually ending the session at $4.29, with a gain of 1.42% or 0.06 points. The heightened volatility saw the trading volume jump to 10,251 shares. Company has a market cap of $109 M.
In a different news, on Dec 14, 2015, Kathleen P. Bloch (CFO) purchased 2,125 shares at $7.05 per share price. According to the SEC, on Nov 2, 2015, Vincent Capponi (Chief Operating Officer) sold 4,000 shares at $7.50 per share price. On Oct 19, 2015, Al Kraus (director) sold 6,774 shares at $6.22 per share price, according to the Form-4 filing with the securities and exchange commission.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company utilizes blood purification to modulate inflammation for treating multiple organ failure illnesses and cardiac surgery. The Company’s purification technologies are based on biocompatible porous polymer beads that can remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s product CytoSorb is approved in the European Union as an extracorporeal cytokine filter designed to reduce the cytokine storm that could cause inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. The Company also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others. In addition CytoSorb can be used in conditions such as cardiac surgery autoimmune disease flares among others.